rivastigmine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 65 Diseases   14 Trials   14 Trials   1875 News 


«12345678910111213...1617»
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Rivastigmine for the management of anticholinergic delirium. (Pubmed Central) -  Mar 22, 2024   
    Rivastigmine can be used to treat anticholinergic delirium. In our case series oral rivastigmine appeared more effective than transdermal rivastigmine.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Decoding Medication Adherence, Mode of Prescription Filling, and Health Care Resource Utilization in Alzheimer () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2014;    
    Mail-ordered prescriptions displayed superior adherence, underlining the potential impact on patient outcomes. Ongoing research into healthcare resource utilization will offer a more holistic understanding of the implications for clinical practice and healthcare policy.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Case Report: Two Patients of Mexican Heritage with Huntington's Disease-like 2 (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3393;    
    Because testing for HDL2 is predominantly recommended in patients with African ancestry, there was delayed HDL2 diagnosis in both patients due to lack of apparent African ancestry. We propose earlier HDL2 testing for HD phenocopies without known African ancestry.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Retrospective data, Review, Journal:  Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis. (Pubmed Central) -  Mar 5, 2024   
    Here we show the significant effects of all available acetylcholinesterase inhibitors on cognitive function in patients with AD. However, further studies are needed to draw valid conclusions about the effects of acetylcholinesterase inhibitors on functional outcomes and adverse events.
  • ||||||||||  Review, Journal:  The VEGFs/VEGFRs system in Alzheimer's and Parkinson's diseases: pathophysiological roles and therapeutic implications. (Pubmed Central) -  Mar 4, 2024   
    Specific VEGFRs targeting, aimed at selective VEGFR-1 inhibition, while preserving VEGFR-2 signal transduction, appears as a promising strategy to hit the molecular mechanisms underlying AD pathology. Moreover, therapeutic VEGF-based approaches can be proposed for PD treatment, with the aim of fine-tuning its brain levels to amplify its neurotrophic/neuroprotective effects while limiting an excessive impact on vascular permeability.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Review, Journal:  Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer's Disease Drug Determination. (Pubmed Central) -  Feb 27, 2024   
    The immobilization of enzymes, nature of the signal recorded and its dependence on the transducer modification are considered and the analytical characteristics of appropriate biosensors are summarized for donepezil, huperzine A, rivastigmine, eserine and galantamine as common anti-dementia drugs. Finally, the prospects for the application of AChE-based biosensors in clinical practice are discussed.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Journal:  Effectiveness of Novel Drug Delivery System using Curcumin in Alzheimer's Disease. (Pubmed Central) -  Feb 27, 2024   
    However, its proven neuroprotective activity is hampered by many factors, such as poor water solubility and bioavailability. Therefore, many novel formulations have been designed to improve its bioavailability with methods such as 1) Micellar Solubilization, 2) Cyclodextrin Complexation, 3) Crystal Modification, and 4) Particle Size Reduction, etc. The current chapter aims to summarize various novel formulations of curcumin and their effectiveness in treating AD.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Synthesis of a Rivastigmine and Insulin Combinational Mucoadhesive Nanoparticle for Intranasal Delivery. (Pubmed Central) -  Feb 24, 2024   
    These results highlight the potential of a new drug delivery system as a promising approach for enhancing nasal transport efficiency. These combinational mucoadhesive NPs offer a novel strategy for the simultaneous cerebral delivery of rivastigmine and insulin, which could prove helpful in developing effective treatments of AD and other neurodegenerative conditions.
  • ||||||||||  Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
    FDA event, Preclinical, Journal:  Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs against Onchocerca gutturosa in Gambia. (Pubmed Central) -  Feb 24, 2024   
    The findings revealed that 44 drugs produced marginal/moderate activity (50-99% motility and/or MTT reductions) including cefuroxime sodium, methenamine, primaquine phosphate and rivastigmine tartrate, while 23 drugs produced good activity (100% motility reductions and significant MTT reductions), including atovaquone, isradipine, losartan, rifaximin, cefaclor and pyrantel pamoate. Although this study represents only a first step, some of the identified hits indicate there are potential anti-Onchocerca drug candidates worthy of further investigation.
  • ||||||||||  Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, donanemab (LY3002813) / Eli Lilly
    Journal:  In Silico Investigation of Novel Compounds as Inhibitors of Acetylcholinesterase Enzyme for the Treatment of Alzheimer's Diseases. (Pubmed Central) -  Feb 19, 2024   
    Currently, two immunotherapy drugs that target amyloid protein (donanemab and lecanemab) are being considered for the treatment of Alzheimer's disease at an early stage...Finally, further literature studies revealed that Zoladex affects memory reduction; therefore, it was dropped as a possible repurposed drug. Our research showed that CHEMBL-1240685 is a potential compound that could be investigated for the inhibition of anticholinesterase enzyme and might be another drug molecule that could be used to treat Alzheimer's disease.
  • ||||||||||  Review, Journal:  Insights into the management of Lewy body dementia: a scoping review. (Pubmed Central) -  Feb 9, 2024   
    Together with that, levodopa, antipsychotics, armodafinil, piracetam, and traditional medications like yokukansan were also used, when indicated...Talking about recent advances in the treatment of LBD, various disease-modifying therapies like ambroxol, neflamapimod, irsenontrine, nilotinib, bosutinib, vodobatinib, clenbuterol, terazosin, elayta, fosgonimeton, and anle138b are emerging out...With the different pharmacological and nonpharmacological modalities we have for treatment of LBD, all of them offer symptomatic relief only. Being a degenerative disease, definite cure of the disease can only be possible with regenerative measures.
  • ||||||||||  Bambec (bambuterol) / Teva
    Journal:  Rivastigmine-Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors. (Pubmed Central) -  Jan 15, 2024   
    Further investigations indicated that MTR-3 (IC > 100,000 nM, IC = 78 nM) was the best compound in the series, showing high butyrylcholinesterase selectivity and inhibition potency, the potential to permeate the blood-brain barrier, and longer-lasting BChE inhibition than bambuterol. These compounds could be used to discover novel specific BChE inhibitors for the treatment of Alzheimer's disease.
  • ||||||||||  Aduhelm (aducanumab) / Eisai, Biogen
    Review, Journal:  Tryptamine: A privileged scaffold for the management of Alzheimer's disease. (Pubmed Central) -  Dec 18, 2023   
    Several tryptamine-based hybrid analogs are currently being investigated as multifunctional agents for the development of novel hybrids for AD treatment. Thus, this review article aims to provide in-depth insights into the research progress and strategies for designing multifunctional agents used in Alzheimer's therapy.
  • ||||||||||  donepezil / Generic mfg., rivastigmine / Generic mfg.
    Journal:  Synthesis and neuroprotective activity of 3-aryl-3-azetidinyl acetic acid methyl ester derivatives. (Pubmed Central) -  Dec 4, 2023   
    Furthermore, the neuroprotective activity of the prepared compounds was evaluated in models associated with Parkinson's disease (salsolinol-induced) and aspects of Alzheimer's disease (glutamate-induced oxidative damage). Compound 28 showed the highest neuroprotective effect in both salsolinol- and glutamate-induced neurodegeneration models, and its protective effect in the glutamate model was revealed to be driven by a reduction in oxidative stress and caspase-3/7 activity.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Journal:  Consumption of drugs for Alzheimer's disease on the Brazilian private market. (Pubmed Central) -  Nov 21, 2023   
    The consumption of medicines indicated to treat Alzheimer's disease tripled in Brazil between 2014 and 2020, which may relate to the increase in the prevalence of the disease in the country, greater access to health services, and inappropriate use. This challenges managers and healthcare providers due to population aging and the increased prevalence of chronic-degenerative diseases.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Review, Journal:  Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer's disease. (Pubmed Central) -  Nov 13, 2023   
    Their design strategies, structure-activity relationships (SARs), and molecular docking studies with AChE and MAO-B were analysed and discussed, giving valuable insights for the subsequent development of AChE and MAO-B dual inhibitors. Challenges in the development of balanced and potent AChE and MAO-B dual inhibitors were noted, and corresponding solutions were provided.
  • ||||||||||  Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Cognex (tacrine) / Shionogi
    A historical review of interventions for Alzheimer's disease (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_14220;    
    The literature indicates that these FDA-approved pharmacological interventions have modest effects in slowing the progression and symptoms of AD.However, controversy arose in 2021 when the FDA granted accelerated approval to aducanumab, the first monoclonal antibody treatment for AD...In 2023, lecanemab, another monoclonal antibody treatment, also received FDA accelerated approval, despite criticism concerning its efficacy and safety.Nevertheless, published data suggest that pharmacological treatments for AD are effective in treating symptoms of AD...Several studies have demonstrated that behavioral lifestyle modifications, such as aerobic exercises, can be a treatment recommendation for AD. For instance, physical exercise has long been recognized to promote improved memory function and cognitive health, presumably by protecting against hippocampal volume loss in older adults.Although there are significant advancements in developing treatment recommendations for AD, further research is warranted on the efficacy of AD treatments, including both pharmacotherapy and non-pharmacotherapy options.
  • ||||||||||  rivastigmine / Generic mfg., haloperidol / Generic mfg.
    SUVN-I7016031: A Novel M1-receptor Positive Allosteric Modulator (M1-PAM) Alleviates Parkinson (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_8727;    
    Observed effects with SUVN-I7016031 were more prominent during week-7 relative to week-2. SUVN-I7016031 showed potential in alleviating haloperidol-induced Parkinson's disease associated cognitive impairment in a preclinical model reflecting PD dementia.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Clinical, Retrospective data, Journal:  Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis. (Pubmed Central) -  Oct 22, 2023   
    An association with ChEI treatment was shown in the AD subgroup for delusions (-0.08; 95% CI, -0.14 to -0.03; P?=?.006) and hallucinations (-0.09; 95% CI, -0.14 to -0.04; P?=?.003) and in the PD subgroup for delusions (-0.14; 95% CI, -0.26 to -0.01; P?=?.04) and hallucinations (-0.08, 95% CI -0.13 to -0.03; P?=?.01). The results of this individual participant data meta-analysis suggest that ChEI treatment improves psychotic symptoms in patients with AD and PD with small effect sizes.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Trial completion date, Trial primary completion date:  Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) -  Oct 10, 2023   
    P3,  N=600, Not yet recruiting, 
    This is the first article investigating the effect of different AChEIs on EEG patterns in patients with AD. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Trial completion date, Trial primary completion date:  Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL) (clinicaltrials.gov) -  Oct 6, 2023   
    P4,  N=1205, Not yet recruiting, 
    A randomized sham-controlled trial is warranted to confirm the therapeutic effects of HD- tDCS and examine how long effects may persist. Trial completion date: Sep 2021 --> Sep 2027 | Trial primary completion date: Mar 2018 --> Apr 2027
  • ||||||||||  Nuplazid (pimavanserin) / Acadia Pharma
    Journal:  Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series. (Pubmed Central) -  Sep 30, 2023   
    Conversely, all 4 patients tolerated pimavanserin well, and 3 of the 4 patients experienced significant improvement of psychosis (eg, fewer hallucinations, fewer delusions, reduced paranoia, and/or reduced distress or agitation related to hallucinations and delusions) when prescribed pimavanserin. CONCLUSIONS This case series suggests that pimavanserin is tolerable in older males with DLB and that it may be useful for the reduction of distressful hallucinations, delusions, and paranoia in patients with DLB.
  • ||||||||||  rivastigmine / Generic mfg., duloxetine / Generic mfg.
    Trial completion date, Trial primary completion date:  Quality Improvement and Practice Based Research in Neurology Using the EMR (clinicaltrials.gov) -  Sep 28, 2023   
    P4,  N=3300, Enrolling by invitation, 
    CONCLUSIONS This case series suggests that pimavanserin is tolerable in older males with DLB and that it may be useful for the reduction of distressful hallucinations, delusions, and paranoia in patients with DLB. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Review, Journal:  Carbamate as a potential anti-Alzheimer's pharmacophore: A review. (Pubmed Central) -  Sep 11, 2023   
    In this review, we summarize the last 10 years of research conducted on the modification of carbamate with different substituents which primarily target ChE inhibition, reduce oxidative stress, and modulate A? aggregation.
  • ||||||||||  Nuplazid (pimavanserin) / Acadia Pharma
    Rapid cognitive decline and new-onset psychosis after GPi DBS in a severe GBA mutation carrier: a case demonstrating the importance of genetic screening pre-DBS () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1982;    
    She was treated with Sertraline, Alprazolam prn, and Temazepam...Over the next 9 months, she required titration of Rivastigmine, Quetiapine, Pimavanserin, Gabapentin, and Clozapine but symptoms worsened and she had progressive visual and auditory hallucinations, delusional jealousy, Capgras syndrome, and paranoia... This case report contributes to the growing body of evidence of impact of DBS in mutation carriers and highlights the importance of genetic testing, counseling and comprehensive neuropsychological assessment in pre-surgical decision-making.